Skip to main content

Table 2 Summary of injection-site reactions in pooled EVOLVE-1, EVOLVE-2, and REGAIN (placebo-controlled analysis set)

From: Evaluation of injection-site-related adverse events with galcanezumab: a post hoc analysis of phase 3 studies in participants with migraine

 Placebo
(N = 1451)
GMB 120 mg
(N = 705)
GMB 240 mg
(N = 730)
Any/all ISRs, n (%)183 (12.6)128 (18.2)166 (22.7)
ISRs excluding pain, n (%)60 (4.1)70 (9.9)106 (14.5)
ISRs, n (%)
 IS pain138 (9.5)71 (10.1)85 (11.6)
 Unspecified ISR14 (1.0)22 (3.1)45 (6.2)
 IS erythema20 (1.4)20 (2.8)29 (4.0)
 IS pruritus2 (0.1)15 (2.1)24 (3.3)
 IS bruising9 (0.6)4 (0.6)10 (1.4)
 IS swelling1 (0.1)8 (1.1)4 (0.6)
 IS rash2 (0.1)6 (0.9)4 (0.6)
 IS induration1 (0.1)3 (0.4)3 (0.4)
 IS discomfort3 (0.2)3 (0.4)2 (0.3)
 IS hematoma7 (0.5)1 (0.1)3 (0.4)
 IS hypersensitivity01 (0.1)3 (0.4)
 IS mass03 (0.4)0
 IS haemorrhage2 (0.1)1 (0.1)1 (0.1)
 IS inflammation01 (0.1)1 (0.1)
 IS irritation3 (0.2)1 (0.1)1 (0.1)
 IS urticarial1 (0.1)1 (0.1)1 (0.1)
 IS discoloration001 (0.1)
 IS oedema1 (0.1)1 (0.1)0
 IS papules01 (0.1)0
 IS vesicles001 (0.1)
 IS warmth1 (0.1)00
  1. Abbreviations:GMB galcanezumab, n number of participants within each specific category, IS injection-site, ISR injection-site reaction, N number of participants in the intent-to-treat population
  2. Note: All values are for injection-site reactions during the double-blind treatment phase from study start up to 6 months for EVOLVE-1 and EVOLVE-2 and up to 3 months for REGAIN